Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
ADU-S100 ammonium salt (ADUS100; ML RR-S2 CDA; MIW815) is potent STING agonist with anticancer and immunomodulatory activities. STING (stimulator of interferon genes) signaling pathway has attracted considerable attention in cancer immunotherapy due to its capacity to boost vigorous antitumor immunity. ADU-S100 leads to potent and systemic tumor regression and immunity. ADU-S100 has the potential to be used in cancer immunotherapy. It elicits potent and durable anti-tumor immunity when administered intratumorally in pre-clinical syngeneic tumor models. As of 2018, it has entered phase I clinical trials for the treatment of cancer. Clinical candidate STING agonist ADU-S100 (S100) is used in an intratumoral dosing regimen optimized for adaptive immunity to uncover requirements for a T cell-driven response compatible with checkpoint inhibitors (CPIs).
ln Vitro |
ADU-S100 ammonium salts have several characteristics that improve stability and lipophilicity in comparison to endogenous and pathogen-derived cyclic dinucleotides (CDNs), thereby significantly enhancing STING signals [1]. In THP-1 human monocytes, ADU-S100 produced more type I IFN than CDA. Disulfide mixed-linked cyclic dinucleotide (CDN) derivatives, on the other hand, effectively activated all five hSTING alleles, including the refractory hSTINGREF and hSTINGQ alleles (ML RR-CDA, ML RR-S2 CDG, and ML RR-S2 cGAMP). In comparison to endogenous ML cGAMP and the TLR3 agonist Poly I:C, ADU-S100 induced the highest expression of IFN-β and the proinflammatory cytokines TNF-α, IL-6, and MCP-1 on a molar equivalent basis. In mouse bone marrow macrophages (BMM), ADU-S100 was also found to induce STING aggregation and induce TBK1 and IRF3 phosphorylation. When compared to ML cGAMP, ADU-S100 induces noticeably higher levels of IFN-α [1].
|
---|---|
ln Vivo |
ADU-S100 outperformed endogenous ML cGAMP in its anti-tumor control capacity. In B16 tumor-bearing mice, a dose response study of ADU-S100 compounds was carried out to ascertain the best anti-tumor dose level that would maximize tumor antigen-specific CD8+ T cell responses and increase long-term survival to 50%[1].
|
References |
[1]. Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018-30
|
Molecular Formula |
C₂₀H₃₀N₁₂O₁₀P₂S₂
|
---|---|
Molecular Weight |
724.60
|
CAS # |
1638750-96-5
|
Related CAS # |
ADU-S100 disodium salt;1638750-95-4;ADU-S100 enantiomer ammonium salt;ADU-S100;1638241-89-0
|
SMILES |
OC1([H])[C@](O[P@]([S-])(OC[C@](O[C@@H](N2C3=NC=NC(N)=C3N=C2)[C@@H]4O)([H])[C@@]4([H])O5)=O)([H])[C@H](N6C7=NC=NC(N)=C7N=C6)O[C@]1([H])CO[P@]5([S-])=O.[NH4+].[NH4+]
|
Synonyms |
ADU-S100ML RR-S2 CDA MIW-815 ML RR-S2 CDA (ammonium salt MIW815 ammonium salt
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~100 mg/mL (~138.01 mM)
DMSO : ~15 mg/mL (~20.70 mM) MEthanol : ~5 mg/mL (~6.90 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 50 mg/mL (69.00 mM) (saturation unknown) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3801 mL | 6.9004 mL | 13.8007 mL | |
5 mM | 0.2760 mL | 1.3801 mL | 2.7601 mL | |
10 mM | 0.1380 mL | 0.6900 mL | 1.3801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.